3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
58
Sarcoma
39
Neoplasm Metastasis
22
Neoplasms
20
Ovarian Neoplasms
17
Breast Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Recurrence
7
Leiomyosarcoma
7
Kidney Neoplasms
7
Melanoma
6
Liposarcoma
6
Hemangiosarcoma
6
Glioblastoma
6
Fallopian Tube Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Neurofibrosarcoma
5
Lung Neoplasms
5
Urinary Bladder Neoplasms
4
Sarcoma, Synovial
4
Pancreatic Neoplasms
4
Osteosarcoma
4
Histiocytoma, Malignant Fibrous
4
Dermatofibrosarcoma
4
Clear-cell metastatic renal cell carcinoma
4
Chondrosarcoma, Extraskeletal Myxoid
4
Uterine Cervical Neoplasms
3
Solid Tumors
3
Small Cell Lung Carcinoma
3
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Refractory or Recurrent Solid Tumor
×
pazopanib
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled